Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Ross C. Donehower(Johns Hopkins University), Ірина Давиденко(State Healthcare Institution "Regional Clinical Oncological Dispensary"), S. Tjulandin(Russian Cancer Research Center NN Blokhin), Andrzej Deptała(Central Clinical Hospital), Mark Harrison(Mount Vernon Hospital), S S Nirni(Cancer Institute (WIA)), K C Lakshmaiah(Kidwai Memorial Institute of Oncology), Anne Thomas(University of Leicester), Yizhou Jiang(Amgen (United States)), Min Zhu(Amgen (United States)), Rui Tang(Amgen (United States)), Abraham Anderson(Amgen (United States)), Sarita Dubey(Amgen (United States)), Kelly S. Oliner(Amgen (United States)), Elwyn Loh(Amgen (United States))
Cited by 261
Abstract
Related Papers
No related papers found
Powered by citation graph analysis